US20090170713A1 - High throughput screening of mutagenized populations - Google Patents

High throughput screening of mutagenized populations Download PDF

Info

Publication number
US20090170713A1
US20090170713A1 US12/088,794 US8879406A US2009170713A1 US 20090170713 A1 US20090170713 A1 US 20090170713A1 US 8879406 A US8879406 A US 8879406A US 2009170713 A1 US2009170713 A1 US 2009170713A1
Authority
US
United States
Prior art keywords
sequence
sequencing
primers
mutation
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/088,794
Other languages
English (en)
Inventor
Michael Josephus Theresia Van Eijk
Adrianus Johannes Van Tunen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keygene NV
Original Assignee
Keygene NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37709618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090170713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Keygene NV filed Critical Keygene NV
Priority to US12/088,794 priority Critical patent/US20090170713A1/en
Assigned to KEYGENE N.V reassignment KEYGENE N.V ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VAN EIJK, MICHAEL JOSEPHUS THERESIA, VAN TUNEN, ADRIANUS JOHANNES
Publication of US20090170713A1 publication Critical patent/US20090170713A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/13—Plant traits

Definitions

  • the present invention in the fields of molecular biology and genetics relates to improved strategies for identifying mutations in populations, based on the use of high throughput sequencing technologies.
  • the invention further provides for kits that can be applied in the methods.
  • Mutagenized populations represent complementary tools for gene discovery, as such populations axe commonly used to screen known genes for loss-of-function mutations or assessing phenotype changes in organisms with the mutated gene.
  • the rate-limiting step is the screening work associated with identification of, respectively, organisms carrying a mutation in the gene of interest. Below, the principles of such populations and the screening methods are described in more detail and more efficient screening methods are presented which increase the value of these tools for gene-discovery.
  • TILLING Tumitted Induced Local Lesions In Genomes
  • EMS ethyl methane sulfonate
  • ionizing radiation fast neutron bombardment
  • a TILLING population generally contains a sufficient number of plants to cover all genes with multiple independent mutations (5-20 per gene).
  • a mutagenized plant population used in TILLING therefore usually consist of 3000-10,000 plants and can be used in two ways:
  • Reverse Genetics is the most common way of using TILLING populations.
  • a gene of interest is identified, e.g., by transcript profiling or a candidate gene approach, and the question to be answered is whether this gene affects a particular phenotypic trait of interest.
  • the challenge therefore is to identify one (or several) plants with loss-of-function mutations in this gene. This is commonly performed in a multi-step screening process, typically comprising the following steps:
  • PCRs are repeated on individual DNAs of the plants in the positive pools, followed by bi-directional Sanger sequencing.
  • Plants harboring a mutation are grown and out-crossed to wild-type to establish causal relationship between the mutation and the observed phenotype change.
  • CEL I screening (steps 3-5 above) is that pre-screening the pooled samples saves costs over sequencing all plants individually by Sanger sequencing.
  • CEL I screening is cost-saving compared to sequencing PCR products of all plants separately.
  • CEL I screening involves running gels and scoring, a relatively cumbersome process that requires confirmation of mutations from the second strand as gel-patterns are not always clear-cut.
  • a third disadvantage is that CEL I screening is relatively insensitive to mutation detection at the termini of the PCR product which may lead to some mutations going undetected. Further disadvantages of CEL I are that it has been found that the enzyme is extremely sensitive to reaction conditions such as salt concentrations. This makes that the enzyme can only be used in a limited number of buffers, thereby hampering the broad use of CEL I. Another practical disadvantage associated with the application of CEL I is that the enzyme is not reliable in cutting all mismatched heteroduplexes.
  • CEL I screening is incapable of distinguishing missense mutations (which are the most prevalent) from non-sense mutations, causing a great deal of screening work carried out on positive pools without yielding interesting mutations.
  • Plants of the mutagenized population are grown and phenotyped for traits of interest. Plants with an interesting phenotype are then crossed to a wild-type plant to out-cross mutations that axe not linked to the phenotype of interest. Finally, the mutated gene responsible for the phenotype of interest is identified by positional cloning (using genetic markers), analogous to mapping QTL in conventional genetic mapping populations (F2, RIL etc). Although theoretically possible, mutagenized populations are not commonly used this way.
  • the present invention was made in part improve the existing strategies for screening of mutagenized populations. It is an object of the invention to provide efficient methods for screening large populations for the presence of mutations and to improve efficient assessment of the mutations for impact on gene function, i.e., to reduce the amount of effort expended on screening mutations that do not lead to altered gene functions.
  • the present methods were designed to avoid the use of the CEL I enzyme or its equivalents.
  • TILLING populations populations wherein mutations have been introduced using (synthetic) mutagenic or DNA damaging oligonucleotides or, i.e. by Targeted Nucleotide Exchange (TINE) or by Region Targeted Mutagenesis (RTM), or populations that contain naturally occurring mutations such as Single nucleotide polymorphisms (SNPs), small insertions and deletions, and variations in microsatellite repeat number could be efficiently screened for the presence of mutations of interest.
  • TINE Targeted Nucleotide Exchange
  • RTM Region Targeted Mutagenesis
  • TILLING or “Targeting induced local lesions in genomes” is a general reverse genetic strategy providing an allelic series of induced (point) mutations by random chemical or physical mutagenesis in combination with PCR-based screening to identify point mutations in a region of interest.
  • regions of interest are amplified by PCR.
  • Heteroduplexes between wild-type fragments and fragments harboring an induced mutation are formed by denaturing and reannealing PCR products. These heteroduplexes are cleaved by CEL I and cleaved products are resolved. Throughput can be increased by pooling. Following discovery of PCR products harboring sequence differences in a pool, PCR products included in the pool are commonly screened again by Sanger sequencing of individual PCR products, thereby identifying the mutant plant and the exact sequence difference in the mutated gene.
  • “Mutagenized Population” refers to a population of organisms (usually plants, but other organisms, including animals such as Drosophila and mice may be used to create a mutagenized populations; Schimenti et al., 1998 , Genome Research 8:698-710) that have been subjected to mutagenesis (chemical or physical) to yield a library of mutants.
  • TILLING populations may vary widely in size, and for certain purposes, partial TILLING populations can be used that contain 90, 80 70, 60, 50, 40 30 or even only 20% of the original population.
  • populations can be used wherein the population is not mutagenized but comprises sub-populations that contain naturally occurring mutations such as Single nucleotide polymorphisms (SNPs), small insertions and deletions, and variations in microsatellite repeat number.
  • SNPs Single nucleotide polymorphisms
  • These populations are particularly advantageous when mutagenized populations are not readily accessible humans) or where already large germplasms are available. See for instance Comai et al., The Plant Journal, 2004, 37, 778-786.
  • Such a population can be used in combination with a ‘reference DNA’.
  • Targeted nucleotide exchange is a process by which a synthetic oligonucleotide, partially complementary to a site in a chromosomal or an episomal gene directs the reversal of a single nucleotide at a specific site.
  • TNE has been described using a wide variety of oligonucleotides and targets. Some of the reported oligonucleotides are RNA/DNA chimeras, contain terminal modifications to impart nuclease resistance.
  • Region targeted mutagenesis is a process by which double-strand breaks at a predefined target site in the genomic DNA are artificially created, resulting in repair of the break by one of various available cellular repair mechanisms, mostly leading to mutations at the site of the break. Double-strand breaks may be created by introduction into the cell nucleus of zinc-finger nucleases (e.g. see Lloyd et al. 2005), meganucleases such as I-Sce1 (Epinat et al., 2003), or triplex-forming oligonucleotides coupled to mutagenic chemical groups (Havre et al., 1993).
  • Nucleic acid A nucleic acid, as used herein, may include any polymer or oligomer of nucleotides with pyrimidine and purine bases, preferably cytosine, thymine (or uracil), adenine and guanine, respectively (See Lehninger, Principles of Biochemistry , at 793-800 (Worth Pub. 1982) which is herein incorporated by reference in its entirety for all purposes). Any deoxyribonucleotide, ribonucleotide or peptide nucleic acid component, and any chemical variant thereof, such as those with methylated, hydroxymethylated or glycosylated forms of these bases, and the like, are included.
  • the polymers or oligomers may be heterogeneous or homogeneous in composition, and may be isolated from naturally occurring sources or may be artificially or synthetically produced.
  • a nucleic acid may be DNA or RNA, or a mixture thereof, and may exist permanently or transiently in single-stranded or double-stranded form, including homoduplexes, heteroduplexes, and hybrid states.
  • Tagging refers to the addition of a tag or label to a nucleic acid in order to be able to distinguish it from a second or further nucleic acid. Tagging can be performed, for example, by the addition of a sequence identifier during amplification by using tagged primers or by any other means known in the art. Such a sequence identifier can be a unique base sequence of varying but defined length uniquely used for identifying a specific nucleic acid sample. Typical example are ZIP sequences. Using such a tag, the origin of a sample can be determined upon further processing. In the case of combining processed products originating from different nucleic acid samples, the different nucleic acid samples are generally identified using different tags.
  • Tagged library refers to a library of tagged nucleic acids.
  • Sequence analysis refers to determining the order of nucleotides (base sequences) in a nucleic acid sample, e.g., DNA or RNA.
  • “Aligning and alignment” mean the comparison of two or more nucleotide sequences based on the presence of short or long stretches of identical or similar nucleotides. Several methods for alignment of nucleotide sequences are known in the art, as will be further explained below. Sometimes the terms “assembly” or “clustering” are used as synonyms.
  • HITS High-throughput screening
  • Primer in general refers to DNA strands which can prime the synthesis of DNA.
  • DNA polymerase cannot synthesize DNA de novo without primers: it can only extend an existing DNA strand in a reaction in which the complementary strand is used as a template to direct the order of nucleotides to be assembled.
  • the synthetic oligonucleotide molecules which are used in a polymerase chain reaction (PCR) are referred to herein as primers.
  • Primers with increased affinity are primers with modified nucleotides such as PNA or LNA, which increases their thermal stability and allows for allele-specific amplification based on single nucleotide sequence differences. In order to achieve this, one or several modified nucleotides are often included, preferably at the 3′-end of the primer.
  • DNA amplification is typically used to denote the in vitro synthesis of double-stranded DNA molecules using PCR. It is noted that other amplification methods exist and they may also be used in the present invention.
  • FIG. 1 Schematic representation of clustered sequences resulting from shotgun sequencing a gene to identify EMS-induced mutations. Mutations are lighter, sequence errors darker colored. Sequence errors are expected to be observed randomly and most often just once.
  • FIG. 2 Schematic representation of clustered tagged sequencing resulting from a 100 bp gene region amplified with 4 bp-tagged PCR primers from a 3-D pooled library. Mutations are lighter, sequence errors darker colored. Plant IDs are known for mutations identified by 3 tags (1,2,3) and (4,5,6) but not for those identified by less than 2 tag (7,8). Sequence errors are expected to be observed randomly and just once.
  • FIG. 3 Illustration of the system of long and short PCR primers to use in tagging the sequences.
  • FIG. 4 Agarose gel estimation of the PCR amplification yield of eIF4E exon 1 amplification for each of the 29 3D pools.
  • the invention is directed to a method for the detection of a mutation in a target sequence in a member of a mutagenized population comprising the steps of:
  • the isolation of DNA is generally achieved using common methods in the art such as the collection of tissue from a member of the population, DNA extraction (for instance using the Q-Biogene fast DNA kit), quantification and normalization to obtain equal amounts of DNA per sample.
  • DNA extraction for instance using the Q-Biogene fast DNA kit
  • quantification for instance using the Q-Biogene fast DNA kit
  • normalization to obtain equal amounts of DNA per sample.
  • the present invention is illustrated based on a TILLING population of 3072 plants and a gene of 100 bp.
  • the pooling of the isolated DNA can for instance be achieved using a 3-dimensional pooling scheme (Vandenbussche et al., 2003 , The Plant Cell, 15: 2680-93).
  • the pooling is achieved preferably using equal amounts of DNA.
  • the pooling step typically serves to identity the plant containing an observed mutation after one round of PCR screening. Pooling of the DNA further serves to normalize the DNAs prior to PCR amplification to provide for a more equal representation in the libraries for sequencing.
  • the additional advantage of the pooling of the DNA is that not all sequences have to be determined separately, but that the pools allow for rapid identification of the sequences of interest, in particular when tagged libraries are used. This facilitates the screening of large or complex populations in particular.
  • the amplification of the target sequence with a pair of optionally labeled primers from the pools can be achieved by using a set of primers that have been designed to amplify the gene of interest.
  • the primers may be labeled to visualize the amplification product of the gene of interest.
  • the amplification products are pooled, preferably in equal or normalized amounts to thereby create a library of amplification products.
  • the amplification products in the library may be randomly fragmented prior to sequencing of the fragments in case the PCR product length exceeds the average length of the sequence traces. Fragmentation can be achieved by physical techniques, i.e., shearing, sonication or other random fragmentation methods.
  • step (f) at least part, but preferably the entire, nucleotides sequence of at least part of, but preferably of all the fragments contained in the libraries is determined.
  • the fragmentation step is optional. For instance, when the read length of the sequencing technique and the PCR fragments length are about the same, there is no need for fragmentation. Also in the case of larger PCR products this may not be necessary if it is acceptable that only part of the PCR product is sequenced for instance in case of 1500 bp PCR product and read length of 400 (from each side) 700 bp remain unsequenced.
  • the sequencing may in principle be conducted by any means known in the art, such as the dideoxy chain termination method (Sanger sequencing), but this is less preferred given the large number of sequences that have to be determined. It is however preferred and more advantageous that the sequencing is performed using high-throughput sequencing methods, such as the methods disclosed in WO 03/004690, WO 03/054142, WO 2004/069849, WO 20041070005, WO 2004/070007, and WO 2005/003375 (all in the name of 454 Life Sciences), by Seo et al. (2004) Proc. Natl. Acad. Sci. USA 101:5488-93, and technologies of Helios, Solexa, US Genomics, etcetera, which are herein incorporated by reference.
  • high-throughput sequencing methods such as the methods disclosed in WO 03/004690, WO 03/054142, WO 2004/069849, WO 20041070005, WO 2004/070007, and WO 2005/003375 (all in the name
  • sequencing is performed using the apparatus and/or method disclosed in WO 03/004690, WO 03/054142, WO 2004/069849, WO 2004/070005, WO 2004/070007, and WO 2005/003375 (all in the name of 454 Life Sciences), which are herein incorporated by reference.
  • the technology described allows sequencing of 40 million bases in a single run and is 100 times faster and cheaper than competing technology.
  • the sequencing technology roughly consists of 5 steps: 1) fragmentation of DNA and ligation of specific adaptor to create a library of single-stranded DNA (ssDNA); 2) annealing of ssDNA to beads, emulsification of the beads in water-in-oil microreactors and performing emulsion PCR to amplify the individual ssDNA molecules on beads; 3) selection of/enrichment for beads containing amplified ssDNA molecules on their surface 4) deposition of DNA carrying beads in a PicoTiterPlate®; and 5) simultaneous sequencing in at least 100,000 wells by generation of a pyrophosphate light signal.
  • the method will be explained in more detail below.
  • the sequencing comprises the steps of:
  • sequencing adaptors are ligated to fragments within the library.
  • the sequencing adaptor includes at least a “key” region for annealing to a bead, a sequencing primer region and a PCR primer region.
  • adapted fragments are obtained.
  • adapted fragments are annealed to beads, each bead annealing with a single adapted fragment.
  • beads are added in excess as to ensure annealing of one single adapted fragment per bead for the majority of the beads (Poisson distribution).
  • the beads are emulsified in water-in-oil microreactors, each water-in-oil microreactor comprising a single bead.
  • PCR reagents are present in the water-in-oil microreactors allowing a PCR reaction to take place within the microreactors.
  • the microreactors are broken, and the beads comprising D-NA (DNA positive beads) are enriched.
  • the beads are loaded in wells, each well comprising a single bead.
  • the wells are preferably part of a PicoTiterTMPlate allowing for simultaneous sequencing of a large amount of fragments.
  • the sequence of the fragments is determined using pyrosequencing.
  • the PicoTiterTMPlate and the beads as well as the enzyme beads therein are subjected to different deoxyribonucleotides in the presence of conventional sequencing reagents, and upon incorporation of a deoxyribonucleotide a light signal is generated which is recorded. Incorporation of the correct nucleotide will generate a pyrosequencing signal which can be detected.
  • the mutations are identified by clustering of the sequenced fragments in the amplified library. Identification of the mutations is achieved by aligning the determined sequences of the fragments of the libraries. The majority of the sequences are wild-type (not mutated) but the induced mutations and occasional sequencing errors are also observed. As the amplification libraries are sequenced with multifold redundancy (typically about 4- to 5-fold redundant), multiple observations of the same sequence change is indicative of a mutation rather than a sequencing error. See FIG. 1 .
  • the clustering provides alignments of the fragments in the amplified library. In this way for each PCR product in the library, a cluster is generated from sequenced fragments, i.e., a contig of the fragments, is build up from the alignment of the sequence of the various fragments obtained from the fragmenting in step (e).
  • NCBI Basic Local Alignment Search Tool (Altschul et al. 1990) is available from several sources, including the National Center for Biological Information (NCBI, Bethesda, Md.) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. It can be accessed at ⁇ http://www.ncbi.nlmn.ih.gov/BLAST/>. A description of how to determine sequence identity using this program is available at ⁇ http://www.nebi.rlm.nih.gov/BLAST/blast-help.html>.
  • the identified mutations are assessed for a modified function of the associated gene, for instance the introduction of a stop codon. This assessment is performed on the sequence itself, for example by six-frame translation. Once the interesting mutations have been identified, the mutations are further investigated to identify the associated member of the population.
  • an allele specific primer is designed that targets the mutation of interest.
  • the allele specific primer is then used in combination with one of the primers used in the amplification of the pooled DNA samples (either the reverse or the forward primer).
  • One or both of the primers may be labeled.
  • the set of primers is used to amplify the pools of DNA.
  • the positive pools are identified and the mutant plant is identified.
  • the allele specific PCR with the set of primers to screen the 3D pooled DNA sample plates results in the identification of 3 positive pools (one in each dimension), which specifies the library address of the mutant plant.
  • the allele-specific primers comprise alternative nucleotides such as Locked Nucleic Acids (LNA) or Peptide Nucleic Acids (PNA) to increase their specificity.
  • LNA Locked Nucleic Acids
  • PNA Peptide Nucleic Acids
  • Confirmation of the mutation is achieved by amplification of the target sequence from the identified mutant plant. This amplification is performed with the primers from step (c). The nucleotide sequence of the amplified product is determined and by comparison with the consensus sequence, the mutation is identified. The sequencing is preferably performed Sanger sequencing.
  • the invention pertains to a method for the detection of a mutation in a target sequence in a member of a mutagenized population comprising the steps of:
  • the isolation of genomic DNA of the members of the mutagenized population and the pooling of the isolated DNA can be carried out essentially as described above.
  • a part or segment of the target sequence is amplified using a pair of tagged primers that may be labeled.
  • a different primer is used for each pool of each dimension. In the above illustration this means that 44 forward and 44 reverse primers are preferred.
  • each of the forward and reverse primers comprises
  • the length of the sequence primer binding site and the gene specific PCR primer sequence are those that are conventional in common PCR use, i.e., independently from about 10 to about 30 bp with a preference for from 15 to 25 bp.
  • the part or segment of the sequence that is amplified corresponds to a length that can be sequenced in one run using the high throughput sequencing technologies described below.
  • the part or segment has a length of between about 50 bp to about 500 bp, preferably from about 75 bp to about 300 bp and more preferably between about 90 bp and about 250 bp. As stated above, this length may vary with the sequencing technology employed including those yet to be developed.
  • primers forward and/or reverse
  • the specific plant origin of each tag sequence is known as the sequence primer anneals upstream of the tag and as a consequence, the tag sequence is present in each amplification product.
  • both forward and reverse primers are tagged.
  • only on of the forward or reverse primers is tagged. The choice between one or two tags depends on the circumstances and depends on the read length of the high throughput sequencing reaction and/or the necessity of independent validation. In the case of, e.g., a 100 bp PCR product that is sequenced unidirectionally, only one tag is needed.
  • double tagging is useful in combination with bi-directional sequencing as it improves efficiency 2-fold. It further provides the possibility of independent validation in the same step.
  • a 100 bp PCR product is sequenced bi-directionally with two tagged primers, all traces, regardless of orientation, will provide information about the mutation. Hence both primers provide “address information” about which plant contains which mutation.
  • the tag can be any number of nucleotides, but preferably contains 2, 3, 4 or 5 nucleotides. With 4 nucleotides permuted, 256 tags are possible, whereas 3 nucleotides permuted provide 64 different tags. In the illustration used, the tags preferably differ by >1 base, so preferred tags are 4 bp in length. Amplification using these primers results in a library of tagged amplification products.
  • a system of tags can be used wherein the amplification process includes
  • the library preferably comprises equal, amounts of PCR products from all amplified pools.
  • the PCR products in the library are subjected to a sequencing process as disclosed above.
  • the PCR products are attached to beads using the sequence primer binding site that corresponds to the sequence linked to the bead.
  • the present embodiment does not require fragmentation and adapter ligation. Rather, in this embodiment, the adapters have been introduced earlier via the PCR primer design. This improves the reliability of the method.
  • sequencing is performed as described above, i.e., (1) emulsification of the beads in water-in-oil microreactors, (2) emulsion PCR to amplify the individual ssDNA molecules on beads; (3) selection of/enrichment for beads containing amplified ssDNA molecules on their surface, (4) transfer of the DNA carrying beads to a PicoTiterPlate®; and (5) simultaneous sequencing in 100,000 wells by a method that generates a pyrophosphate light signal.
  • Typical output is about 200.000 ⁇ 100-200 bp sequences, representing a 66 fold coverage of all PCR products in the library.
  • Clustering and alignment is performed essentially as described above.
  • the individual plant containing the mutation can be identified using the tags.
  • the combination of the 3 tags denotes the positive pools and the consequently the coordinates of the individual plant in the pools.
  • pooling strategies can be used with the present invention, examples of which are multidimensional pooling (including 3D pooling) or column-, row- or plate pooling.
  • High throughput sequencing methods that can be used here are described, for example, in Shendure et al., Science 309:1728-32. Examples include microelectrophoretic sequencing, hybridization sequencing/sequencing by hybridization (SBH), cyclic-array sequencing on amplified molecules, cyclic-array sequencing on single molecules, non-cyclical, single-molecule, real-time methods, such as, polymerase sequencing, exonuclease sequencing, or nanopore sequencing.
  • SBH hybridization sequencing/sequencing by hybridization
  • real-time methods such as, polymerase sequencing, exonuclease sequencing, or nanopore sequencing.
  • fragments or amplified products should be sequenced with sufficient redundancy.
  • Redundancy permits distinction between a sequencing error and a genuine possible mutation.
  • the redundancy of the sequencing is preferable at least 4, more preferably at least 5, but, as can be seen from the Examples, redundancies of more than 10, preferably more than 25 or even more than 50 are considered advantageous, although not essential for this invention.
  • All mutations can be found with equal probability, irrespective of their position in the PCR product, in particular when the whole target sequence is screened.
  • the method further avoids the use of CEL I digestion, heteroduplex formation and cumbersome gel scoring.
  • the invention is therefore insensitive to pooling limitations associated with CEL I technology.
  • kits may contain one or more compounds selected form the group consisting of: one or more (labeled) primers for a particular gene or trait, mutation- or allele-specific primers.
  • the kits may further contain beads, sequencing primers, software, descriptions for pooling strategies and other components that are known for kits per se.
  • kits are provided that are dedicated to find specific mutations, for instance disease-related mutations.
  • Screening a TILLING population can be advanced by using novel high-throughput sequencing methods, such as that of 454 Life Sciences (Margulies et al., 2005) or Polony Sequencing (Shendure et al., 2005), With the current state-of-the-art, 454 Life Sciences technology produces approximately 20 Mb sequence in a single sequencing run. Read lengths are approximately 100 bp per read. Assuming the screening of a population consisting of 3072 plants for mutations in a 1500 bp gene (as described in the above-cited reference in Chapter 2), two approaches are envisaged and described in more detail below.
  • Genomic DNA of 3072 plants of the TILLING population is isolated.
  • This pooling step serves to permit identification of a plant containing an observed mutation after one round of PCR screening (step 8). Pooling of genomic DNAs further serves to normalize DNAs prior to PCR amplification to increase the probability that all DNAs are represented equally in the sequence library.
  • the 1500 bp gene is amplified from the pooled DNA samples using 1 pair of unlabelled PCR primers.
  • the pooled PCR product library is subjected to shotgun sequencing using conventional technologies (such as those provided by 454 Life Sciences) wherein PCR products are randomly fragmented, amplified on individual beads and sequenced on the bead. Output is approximately 200,000 100 bp sequences, representing 4- to 5-fold coverage of all PCR products in the library).
  • Mutations are assessed for their impact on gene function such as introduction of a stop-codon.
  • An allele-specific primer targeting a mutation of interest (with 3′ Locked Nucleic Acid; LNA; or Peptide Nucleic Acid; PNA) is designed to be used in combination with either the forward or reverse primer used in step 3 to screen the 3-D pooled DNA sample plate. Allele-specific PCR will result in three positive pools (one of each dimension), which specifies the library address of the mutant plant.
  • the mutation is confirmed by amplifying the 1500 bp gene using the primers of step 3, followed by (bi-directional) Sanger sequencing.
  • 100 bp is the Read Length of one 454 Sequence Run
  • Genomic DNA of 3072 plants of the TILLING population is isolated.
  • This pooling step serves to permit identification of the plant containing an observed mutation directly from the sequence data. Pooling of genomic DNAs further serves to normalize DNAs prior to PCR amplification to increase the probability that all DNAs are represented equally in the sequence library.
  • a 100 bp (or 200 bp) region of the gene is amplified from a the pools by PCR using tagged unlabelled PCR primers. This requires 44 forward and 44 reverse primers (one for each pool of each dimension) with the following configuration:
  • a 3 bp tag allows 64 different tag sequences—sufficient to distinguish 44 tags—but tag sequences differing by more than 1 base are preferred.
  • the pooled PCR product library is provided to 454 for sequencing, i.e., PCR products are amplified and sequenced on the beads.
  • Output is approximately 200,000 100 bp sequences, representing 66-fold coverage of all PCR products in the library.
  • the coordinates of the individual plant containing the mutation will be known immediately based on the unique combination of 3 tags sequences that occur in the sequence traces harboring the mutation ( FIG. 2 ).
  • the mutation is confirmed by amplifying the 1500 bp gene using the primers of step 3, followed by (bi-directional) Sanger sequencing.
  • This example describes the screening of a mutant library of tomato by massive parallel sequencing in order to identify point mutations in a specific locus (target gene).
  • the mutant library used is an isogenic library of inbred determinate tomato cultivar M82 consisting of 5075 M2 families derived from EMS mutagenesis treatments. Seeds of each of the 5075 M2 families were stored at 10% RD and 7° C. The origin and characteristics of the library are described in Menda et al. ( Plant J. 38: 861-872, 2004) and in a database on http://zamir.sgn.cornell.edu/mutants/index.htl.
  • Leaf material was harvested from 5 individual greenhouse-grown plants of each of 3072 M2 families randomly chosen from the library. As any mutation occurring in the library will segregate in a Mendelian fashion in the M2 offspring, the pooling of the leaf material of 5 individual M2 plants reduced the likelihood of overlooking any mutation as a consequence of segregation to less than 0.1%.
  • Genomic DNA was isolated from the pooled leaf material using a modified CTAB procedure described by Stuart and Via ( Biotechniques, 14: 748-750, 1993). DNA samples were diluted to a concentration of 100 ng/ ⁇ l in TE (10 mM Tris-HCl pH 8.0, 1 mM: EDTA) and stored at ⁇ 20° C. in 96-well microtitre plates.
  • the isolated DNA samples were normalized to a concentration of 20 ng/ ⁇ l and subsequently pooled 4-fold resulting in 768 samples comprised in eight 96-well microtitre plates. Subsequently, these eight microtitre plates were subjected to a 3D pooling strategy, resulting in 28 pools of DNA.
  • the 3D pooling strategy consisted of pooling together all DNAs in three different manners, thus ensuring that each single 4-fold pool occurs only once in an X-coordinate pool only once in a Y-coordinate pool and only once in a Z-coordinate pool.
  • X-pools were assembled by pooling all DNA samples together per column of eight wells (e.g.
  • the target locus in this example was part of the tomato gene for eucaryotic initiation factor 4E (eIF4E).
  • eIF4E eucaryotic initiation factor 4E
  • This gene has been shown to be involved in susceptibility to infection of potyviruses in Arabidopsis (Duprat et al, Plant J. 32: 997-934, 2002), lettuce (Nicaise et al. Plant Physiol. 132: 1272-1282, 2003) and Solanaceae (Ruffel et al., Plant J. 32: 1067-1075, 2002; Mol. Gen. Genomics 274: 346-353, 2005), and specific mutations in this gene are associated with recessive potyvirus resistance.
  • the mutation screening described in this example was aimed to identify additional mutations in the tomato eIF4E gene as possible sources of new potyvirus resistance.
  • the tomato eIF4E only the cDNA sequence was known (NCBI accession numbers AY723733 and AY723734).
  • Using a PCR approach using primers designed on the basis of the cDNA sequence fragments of the genomic sequence of the eIF4E locus of tomato cultivar Moneyberg were amplified and sequenced. This resulted in a sequence of most of the genomic locus of tomato eIF4E.
  • the locus consists of 4 exons and 3 introns.
  • exon 1 of the gene was chosen as the target sequence (SEQ ID 57).
  • SEQ ID 57 Sequence of exon 1 of tomato Moneyberg eIF4E: ATGGCAGCAGCTGAAATGGAGAGAACGATGTCGTTTGATGCAGCTGAGAA GTTGAAGGCCGCCGATGGAGGAGGAGGAGAGGTAGACGATGAACTTGAAG AAGGTGAAATTGTTGAAGAATCAAATGATACGGCATCGTATTTAGGGAAA GAAATCACAGTGAAGCATCCATTGGAGCATTCATGGACTTTTTGGTTTGA TAACCCTACCACTAAATCTCGACAAACTGCTTGGGGAAGCTCACTTCGAA ATGTCTACACTTTCTCCACTGTTGAAAATTTTTGGGG
  • Primers were designed for the PCR amplification of exon 1 of tomato eIF4E.
  • the forward primers were designed to correspond to the ATG start codon of the Open Reading Frame of exon 1, with 5′ of the ATG a tag sequence of four bases, providing a unique identifier for each of the 28 pools.
  • a 5′-C was added at the far 5′ end of the forward PCR primers. All primers were phosphorylated at their 5′end to facilitate subsequent ligation of adaptors.
  • the sequence and names of the 28 forward primers are listed in Table 1. The tag sequences are underlined.
  • the reverse primers were designed to correspond to basepair position 267 to 287 of exon 1 in the non-coding strand. Again, 5′ of the priming part the same series of tag sequences of four bases were included, providing a identifier for each of the 28 pools. At the far 5′ end of the reverse PCR primers, a 5′-C was added. All primers were phosphorylated at their 5′ end to facilitate subsequent ligation of adaptors. The sequence and names of the 28 reverse primers are listed in Table 2. The tags are underlined.
  • the exon 1 of the target locus was amplified from the 3D pooled DNAs using the forward and reverse primers described above. For each PCR reaction, a forward and a reverse primer were used with identical tags. For the amplification of exon 1 from each of the 28 3D pools, a different set of forward and reverse primers was used.
  • the PCR amplification reaction conditions for each sample were as follows:
  • the RNase-mix consisted of 157.5 ⁇ milliQ-purified water+17.5 ⁇ l RNase.
  • PCR amplifications were performed in a PE9600 thermocycler with a gold or silver block using the following conditions: 2 minutes hot-start of 94° C., followed by 35 cycles of 30 see at 94° C., 30 sec at 53° C., 1 min at 72° C., and a final stationary temperature of 4° C.
  • the PCR amplification efficiency was checked by analysis of 10 ⁇ l of PCR products on a 1% agarose gel.
  • FIG. 4 shows the efficient amplification of exon 1 PCR products from each of the 28 3D pools in comparison to a concentration range of lambda DNA on the same gel.
  • PCR products were mixed and purified using the QIAquick PCR Purification Kit (QIAGEN), according to the QIAquick® Spin handbook (page 18). On each column a maximum of 100 ⁇ l of product was loaded. Products were eluted in 10 mM Tris-EDTA.
  • the ssahaSNP tool reported about all single nucleotide sequence differences and “indels” (single base insertions or deletions as a result of either mutagenesis or erroneous base-calling) of the 454 sequences versus the reference genome. These single nucleotide sequence difference and indel statistics were saved in a database and used for error rate analysis and point mutation identification.
  • the total number of correct sequences obtained from the data processing for all 28 pools combined was 247,052.
  • the number of sequences obtained from each of the different pools and alignment groups ranged from 69 to 7269. On average, each of the 3072 M2 families should be represented 80 times in the total collection of sequences, and each allele 40 times.
  • the single base substitution error rate for both sequence groups combined equals 0.84% for a 165 base stretch, or 0.0051% per base position (0.5 errors per 10,000 bases). This error rate is similar to the one reported by Margulies et al. of 0.004% for individual read substitution errors in test sequences, but much lower than for whole-genome resequencing (0.68%).
  • one such mutation was found in the alignment group corresponding to the reverse primer, at base position 221 of the eIF4E exon 1 sequence.
  • This mutation a G ⁇ A mutation (corresponding to C ⁇ T in the complementary strand) occurred in pool X12 at a frequency of 70 per 10,000 sequences, in pool Y3 at a frequency of 33 per 10,000 and in pool Z6 at 62 per 10,000 sequences.
  • This same mutation at the same position did not occur in any of the other pools, not even at background error rates.
  • the mutation causes an arginine to glutamine substitution. Seeds of this particular M2 family were planted in the greenhouse in order to select for homozygous mutant individuals, that will be used for phenotyping.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nanotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US12/088,794 2005-09-29 2006-09-21 High throughput screening of mutagenized populations Abandoned US20090170713A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/088,794 US20090170713A1 (en) 2005-09-29 2006-09-21 High throughput screening of mutagenized populations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72152805P 2005-09-29 2005-09-29
PCT/NL2006/000467 WO2007037678A2 (fr) 2005-09-29 2006-09-21 Criblage a haut debit de populations mutagenisees
US12/088,794 US20090170713A1 (en) 2005-09-29 2006-09-21 High throughput screening of mutagenized populations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2006/000467 A-371-Of-International WO2007037678A2 (fr) 2005-09-29 2006-09-21 Criblage a haut debit de populations mutagenisees

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/447,871 Continuation US8614073B2 (en) 2005-09-29 2012-04-16 High throughput screening of mutagenized populations

Publications (1)

Publication Number Publication Date
US20090170713A1 true US20090170713A1 (en) 2009-07-02

Family

ID=37709618

Family Applications (12)

Application Number Title Priority Date Filing Date
US12/088,794 Abandoned US20090170713A1 (en) 2005-09-29 2006-09-21 High throughput screening of mutagenized populations
US13/447,871 Active 2026-10-03 US8614073B2 (en) 2005-09-29 2012-04-16 High throughput screening of mutagenized populations
US13/972,152 Active US9376719B2 (en) 2005-09-29 2013-08-21 High throughput screening of mutagenized populations
US15/165,921 Active US9574230B2 (en) 2005-09-29 2016-05-26 High throughput screening of populations carrying naturally occuring mutations
US15/288,253 Active US9657335B2 (en) 2005-09-29 2016-10-07 High throughput screening of populations carrying naturally occurring mutations
US15/400,920 Active US9670542B2 (en) 2005-09-29 2017-01-06 High throughput screening of populations carrying naturally occurring mutations
US15/434,788 Abandoned US20170166962A1 (en) 2005-09-29 2017-02-16 High throughput screening of populations carrying naturally occurring mutations
US15/434,801 Active US9745627B2 (en) 2005-09-29 2017-02-16 High throughput screening of populations carrying naturally occurring mutations
US15/674,126 Abandoned US20170342486A1 (en) 2005-09-29 2017-08-10 High throughput screening of populations carrying naturally occurring mutations
US15/961,542 Active US10233494B2 (en) 2005-09-29 2018-04-24 High throughput screening of populations carrying naturally occurring mutations
US16/267,123 Active US10538806B2 (en) 2005-09-29 2019-02-04 High throughput screening of populations carrying naturally occurring mutations
US16/719,863 Active 2026-11-13 US11649494B2 (en) 2005-09-29 2019-12-18 High throughput screening of populations carrying naturally occurring mutations

Family Applications After (11)

Application Number Title Priority Date Filing Date
US13/447,871 Active 2026-10-03 US8614073B2 (en) 2005-09-29 2012-04-16 High throughput screening of mutagenized populations
US13/972,152 Active US9376719B2 (en) 2005-09-29 2013-08-21 High throughput screening of mutagenized populations
US15/165,921 Active US9574230B2 (en) 2005-09-29 2016-05-26 High throughput screening of populations carrying naturally occuring mutations
US15/288,253 Active US9657335B2 (en) 2005-09-29 2016-10-07 High throughput screening of populations carrying naturally occurring mutations
US15/400,920 Active US9670542B2 (en) 2005-09-29 2017-01-06 High throughput screening of populations carrying naturally occurring mutations
US15/434,788 Abandoned US20170166962A1 (en) 2005-09-29 2017-02-16 High throughput screening of populations carrying naturally occurring mutations
US15/434,801 Active US9745627B2 (en) 2005-09-29 2017-02-16 High throughput screening of populations carrying naturally occurring mutations
US15/674,126 Abandoned US20170342486A1 (en) 2005-09-29 2017-08-10 High throughput screening of populations carrying naturally occurring mutations
US15/961,542 Active US10233494B2 (en) 2005-09-29 2018-04-24 High throughput screening of populations carrying naturally occurring mutations
US16/267,123 Active US10538806B2 (en) 2005-09-29 2019-02-04 High throughput screening of populations carrying naturally occurring mutations
US16/719,863 Active 2026-11-13 US11649494B2 (en) 2005-09-29 2019-12-18 High throughput screening of populations carrying naturally occurring mutations

Country Status (11)

Country Link
US (12) US20090170713A1 (fr)
EP (1) EP1929039B2 (fr)
JP (1) JP5237099B2 (fr)
CN (1) CN101313078B (fr)
AT (1) ATE453728T1 (fr)
AU (1) AU2006295556B2 (fr)
CA (2) CA2910861C (fr)
DE (1) DE602006011486D1 (fr)
DK (1) DK1929039T4 (fr)
ES (1) ES2338459T5 (fr)
WO (1) WO2007037678A2 (fr)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143908A1 (en) * 2006-11-15 2010-06-10 Biospherex, Llc, A Limited Liability Company Multitag sequencing ecogenomics analysis-us
US20120276524A1 (en) * 2009-11-16 2012-11-01 Genomictree, Inc. Genotyping method
US20120322691A1 (en) * 2011-05-13 2012-12-20 Ravi Sachidanandam Pooled adapter strategy for reducing bias in small rna characterization
EP2599877A1 (fr) * 2010-06-30 2013-06-05 BGI Shenzhen Co., Limited Nouvelle méthode de séquençage par pcr et son utilisation dans le génotypage hla
US20140296090A1 (en) * 2008-08-26 2014-10-02 Fluidigm Corporation Assay methods for increased throughput of samples and/or targets
US20150045258A1 (en) * 2012-02-14 2015-02-12 Gnubio, Inc. Cascaded addition of target specific universal adapters to nucleic acids
US9677119B2 (en) 2009-04-02 2017-06-13 Fluidigm Corporation Multi-primer amplification method for tagging of target nucleic acids
US9840732B2 (en) 2012-05-21 2017-12-12 Fluidigm Corporation Single-particle analysis of particle populations
US10266884B2 (en) 2009-04-30 2019-04-23 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10308982B2 (en) 2010-04-05 2019-06-04 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10501786B2 (en) 2011-05-20 2019-12-10 Fluidigm Corporation Nucleic acid encoding reactions
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10774372B2 (en) 2013-06-25 2020-09-15 Prognosy s Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11117113B2 (en) 2015-12-16 2021-09-14 Fluidigm Corporation High-level multiplex amplification
US11332790B2 (en) 2019-12-23 2022-05-17 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11933957B1 (en) 2018-12-10 2024-03-19 10X Genomics, Inc. Imaging system hardware
US11965213B2 (en) 2019-05-30 2024-04-23 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
USRE50065E1 (en) 2012-10-17 2024-07-30 10X Genomics Sweden Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US12071655B2 (en) 2021-06-03 2024-08-27 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
US12076701B2 (en) 2020-01-31 2024-09-03 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US12117439B2 (en) 2019-12-23 2024-10-15 10X Genomics, Inc. Compositions and methods for using fixed biological samples
US12129516B2 (en) 2020-02-07 2024-10-29 10X Genomics, Inc. Quantitative and automated permeabilization performance evaluation for spatial transcriptomics

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463386B1 (fr) 2005-06-15 2017-04-12 Complete Genomics Inc. Analyse d'acide nucléique par des mélanges aléatoires de fragments non chevauchants
CN105039313B (zh) 2005-06-23 2018-10-23 科因股份有限公司 用于多态性的高通量鉴定和检测的策略
US10316364B2 (en) 2005-09-29 2019-06-11 Keygene N.V. Method for identifying the source of an amplicon
DK1929039T4 (en) * 2005-09-29 2014-02-17 Keygene Nv High throughput-screening af mutageniserede populationer
EP2789696B1 (fr) 2005-12-22 2015-12-16 Keygene N.V. Procédé pour la détection de polymorphisme à base AFLP à haut rendement
EP2963127B1 (fr) 2006-04-04 2017-08-16 Keygene N.V. Détection à haut débit de marqueurs moléculaires sur la base de fragments de restriction
CN101801176A (zh) * 2007-09-24 2010-08-11 凯津公司 选择具有特异性突变的植物的方法
EP2227557B1 (fr) * 2007-11-27 2012-12-12 Vib Vzw Évolution dirigée assistée par marqueur
US8592150B2 (en) 2007-12-05 2013-11-26 Complete Genomics, Inc. Methods and compositions for long fragment read sequencing
US9127312B2 (en) 2011-02-09 2015-09-08 Bio-Rad Laboratories, Inc. Analysis of nucleic acids
JP2012508573A (ja) * 2008-11-17 2012-04-12 キージーン・エン・フェー 大量変異解析（ＢｕｌｋｅｄＭｕｔａｎｔＡｎａｌｙｓｉｓ（ＢＭＡ））
WO2010057525A1 (fr) * 2008-11-19 2010-05-27 Fondazione Parco Tecnologico Padano Amorces oligonucléotidiques pour l'indexage nucléotidique de produits d'acp polymorphes et leurs procédés d'utilisation
CA2745853A1 (fr) 2008-12-05 2010-06-10 Keygene N.V. Farnesene synthase
EP2425011A1 (fr) * 2009-04-29 2012-03-07 Hendrix Genetics Research, Technology & Services B.V. Procédé pour former un groupement d'échantillons à des fins de dosage biologique
DK2977455T3 (da) * 2009-06-15 2020-07-13 Complete Genomics Inc Fremgangsmåde til langfragmentaflæsnings-sekventering
CN102791880A (zh) * 2009-12-18 2012-11-21 凯津公司 改进的大突变分析
EP2580351B1 (fr) 2010-06-09 2018-08-29 Keygene N.V. Code-barres de séquences combinatoires pour criblage à haut débit
CN101921842B (zh) * 2010-06-30 2013-08-07 深圳华大基因科技有限公司 Hla-a,b基因分型用pcr引物及其使用方法
CN101921840B (zh) * 2010-06-30 2014-06-25 深圳华大基因科技有限公司 一种基于dna分子标签技术和dna不完全打断策略的pcr测序方法
CN101921841B (zh) * 2010-06-30 2014-03-12 深圳华大基因科技有限公司 基于Illumina GA测序技术的HLA基因高分辨率分型方法
WO2012008831A1 (fr) * 2010-07-13 2012-01-19 Keygene N.V. Génération simplifiée de cartes physiques de novo à partir de banques de clones
CN102409047B (zh) * 2010-09-21 2014-07-23 深圳华大基因科技服务有限公司 一种构建杂交测序文库的方法
WO2012129363A2 (fr) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Détection et analyse d'acide nucléique d'une cellule isolée
WO2012169893A1 (fr) 2011-06-10 2012-12-13 Stichting Technologisch Topinstituut Groene Genetica (Foundation Technological Top Institute Green Genetics) Facteur de transcription modulant la biosynthèse de terpènes
PT2814959T (pt) 2012-02-17 2018-04-12 Hutchinson Fred Cancer Res Composições e métodos para a identificação exata de mutações
PL2828218T3 (pl) 2012-03-20 2021-01-11 University Of Washington Through Its Center For Commercialization Sposoby obniżania współczynnika błędów masywnie równoległej sekwencji dna z wykorzystaniem duplex consensus sequencing
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
JP2014023434A (ja) * 2012-07-24 2014-02-06 Lotte Co Ltd デンタルプラークの細菌叢の解析方法
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR102028375B1 (ko) 2012-09-04 2019-10-04 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR101600899B1 (ko) 2012-12-11 2016-03-09 주식회사 셀레믹스 초병렬적 핵산 합성법을 통한 dna 라이브러리의 동시 합성 방법
WO2014134729A1 (fr) 2013-03-08 2014-09-12 Vineland Research And Innovation Centre Méthode de criblage à haut débit d'une population à la recherche d'éléments comprenant une(des) mutations(s) dans une séquence cible
US9822408B2 (en) 2013-03-15 2017-11-21 Nugen Technologies, Inc. Sequential sequencing
WO2014171898A2 (fr) 2013-04-17 2014-10-23 Agency For Science, Technology And Research Méthode de génération de lectures de séquences étendues
WO2015013681A1 (fr) 2013-07-25 2015-01-29 Bio-Rad Laboratories, Inc. Dosages génétiques
JP2015035212A (ja) * 2013-07-29 2015-02-19 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ターゲットシークエンシングパネルから変異を見つける方法
JP6525473B2 (ja) 2013-11-13 2019-06-05 ニューゲン テクノロジーズ， インコーポレイテッド 複製物配列決定リードを同定するための組成物および方法
EP3074528A1 (fr) * 2013-11-26 2016-10-05 Qiagen GmbH Génération d'amplicons d'adn prêts pour la ligature
ES2693217T3 (es) 2013-12-02 2018-12-10 Personal Genome Diagnostics Inc. Método para evaluar variantes minoritarias en una muestra
CN103617375B (zh) * 2013-12-02 2017-08-25 深圳华大基因健康科技有限公司 聚合酶链式反应产物测序分型的方法及系统
EP3378952B1 (fr) 2013-12-28 2020-02-05 Guardant Health, Inc. Procédés et systèmes de détection de variants génétiques
WO2016012346A1 (fr) 2014-07-25 2016-01-28 Enza Zaden Beheer B.V. Plant de concombre stay green
US10233490B2 (en) 2014-11-21 2019-03-19 Metabiotech Corporation Methods for assembling and reading nucleic acid sequences from mixed populations
US10344336B2 (en) 2015-06-09 2019-07-09 Life Technologies Corporation Methods, systems, compositions, kits, apparatus and computer-readable media for molecular tagging
WO2017058022A1 (fr) 2015-10-02 2017-04-06 Keygene N.V. Procédé de production d'haploïdes et de dihaploïdes subséquents
BR112018006573A2 (pt) 2015-10-02 2018-10-09 método para a produção de plantas haploides e subsequentes haploides duplicadas
CA2911002C (fr) 2015-11-04 2016-11-29 Travis Wilfred BANKS Methode offrant une capacite de traitement elevee de filtrage de population destinee a des membres comprenant des mutations dans une sequence ciblee a l'aide d'analyse de sequence sans alignement
EP4043584A1 (fr) 2015-12-08 2022-08-17 Twinstrand Biosciences, Inc. Adaptateurs améliorés, procédés, et compositions pour le séquençage en double hélice
SG11201805119QA (en) 2015-12-17 2018-07-30 Guardant Health Inc Methods to determine tumor gene copy number by analysis of cell-free dna
EP3199642A1 (fr) 2016-02-01 2017-08-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sélection de plantes à l'aide de séquençage haut débit
CN105734130B (zh) * 2016-03-11 2019-10-25 中国农业科学院生物技术研究所 全基因组范围的植物基因功能鉴定的方法
US11384382B2 (en) 2016-04-14 2022-07-12 Guardant Health, Inc. Methods of attaching adapters to sample nucleic acids
EP3443066B1 (fr) 2016-04-14 2024-10-02 Guardant Health, Inc. Méthodes de détection précoce du cancer
EP3457837A1 (fr) 2016-05-20 2019-03-27 Keygene N.V. Procédé pour la production de plantes haploïdes et double haploïdes successives
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
EP3461274B1 (fr) 2016-09-30 2020-11-04 Guardant Health, Inc. Procédés d'analyse multirésolution d'acides nucléiques acellulaires
WO2018183942A1 (fr) 2017-03-31 2018-10-04 Grail, Inc. Préparation de banques améliorées et leur utilisation pour la correction d'erreurs basées sur le séquençage et/ou l'identification de variants
US10633651B2 (en) 2017-07-10 2020-04-28 Agilent Technologies, Inc. Assay methods and compositions for detecting contamination of nucleic acid identifiers
US11505826B2 (en) 2017-07-12 2022-11-22 Agilent Technologies, Inc. Sequencing method for genomic rearrangement detection
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
WO2019094651A1 (fr) 2017-11-08 2019-05-16 Twinstrand Biosciences, Inc. Réactifs et adaptateurs pour séquençage d'acides nucléiques et procédés de fabrication de tels réactifs et adaptateurs
WO2019121603A1 (fr) 2017-12-18 2019-06-27 Keygene N.V. Mutagénèse chimique du manioc
CN108315396B (zh) * 2018-03-28 2021-07-16 潍坊兴旺生物种业有限公司 一种简单便捷检测snp的新方法
CN112236520A (zh) 2018-04-02 2021-01-15 格里尔公司 甲基化标记和标靶甲基化探针板
CA3100983A1 (fr) 2018-06-06 2019-12-12 The Regents Of The University Of California Procedes de production de bibliotheques d'acides nucleiques et compositions et kits pour leur mise en ƒuvre
KR20210059694A (ko) 2018-07-12 2021-05-25 트윈스트랜드 바이오사이언시스, 인코포레이티드 게놈 편집, 클론 팽창 및 연관된 분야를 규명하기 위한 방법 및 시약
EP3856903A4 (fr) 2018-09-27 2022-07-27 Grail, LLC Marqueurs de méthylation et panels de sondes de méthylation ciblées
US10945844B2 (en) 2018-10-10 2021-03-16 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
CA3117768A1 (fr) 2018-11-28 2020-06-04 Keygene N.V. Enrichissement cible par protection d'endonuclease
JP2020080761A (ja) * 2018-11-28 2020-06-04 大成建設株式会社 植物種の地域性変異特定方法
CN111378557B (zh) 2018-12-26 2023-06-06 财团法人工业技术研究院 用于产生液珠的管状结构及液珠产生方法
CN113661249A (zh) 2019-01-31 2021-11-16 夸登特健康公司 用于分离无细胞dna的组合物和方法
AU2020225760A1 (en) 2019-02-21 2021-08-19 Keygene N.V. Genotyping of polyploids
US20220228163A1 (en) 2019-05-24 2022-07-21 Enza Zaden Beheer B.V. Downy mildew resistant melon plants
CN110904258B (zh) * 2019-12-03 2021-08-17 湖南杂交水稻研究中心 一种高通量靶向鉴定理化诱变植株m1代突变及获取突变体的方法
WO2021116371A1 (fr) 2019-12-12 2021-06-17 Keygene N.V. Manipulation d'acide nucléique semi-solide
JP2023506631A (ja) 2019-12-20 2023-02-17 キージーン ナムローゼ フェンノートシャップ 共有結合で閉端された核酸分子末端を使用したｎｇｓライブラリー調製
US12059674B2 (en) 2020-02-03 2024-08-13 Tecan Genomics, Inc. Reagent storage system
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
WO2021226581A1 (fr) * 2020-05-08 2021-11-11 Baebies, Inc. Regroupement multidimensionnel de codes à barres
MX2023002239A (es) 2020-09-01 2023-03-15 Enza Zaden Beheer Bv Plantas de calabaza resistentes a enfermedades.
WO2022074058A1 (fr) 2020-10-06 2022-04-14 Keygene N.V. Addition de séquence ciblée
US20240002904A1 (en) 2020-11-24 2024-01-04 Keygene N.V. Targeted enrichment using nanopore selective sequencing
EP4251750A1 (fr) 2020-11-25 2023-10-04 Koninklijke Nederlandse Akademie van Wetenschappen Profilage ribosomique dans des cellules individuelles
WO2022207114A1 (fr) 2021-04-01 2022-10-06 Enza Zaden Beheer B.V. Plante cucurbitacée dite « stay green » (toujours verte)
CN113130005B (zh) * 2021-04-12 2022-11-22 中国科学院东北地理与农业生态研究所 一种基于m2群体的候选因果突变位点基因定位的方法
JP2024514169A (ja) 2021-04-15 2024-03-28 キージーン ナムローゼ フェンノートシャップ 共再生難再生性植物体
WO2024121354A1 (fr) 2022-12-08 2024-06-13 Keygene N.V. Séquençage duplex avec extrémités d'adn fermées de manière covalente
WO2024133851A1 (fr) 2022-12-22 2024-06-27 Keygene N.V. Régénération par greffage de cal de protoplastes
WO2024209000A1 (fr) 2023-04-04 2024-10-10 Keygene N.V. Lieurs pour séquençage duplex

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248526B1 (en) * 1997-12-15 2001-06-19 Aventis Behring, Gmbh Labeled primer for use in and detection of target nucleic acids
US20040053236A1 (en) * 2001-03-30 2004-03-18 Mccallum Claire M. Reverse genetic strategy for identifying functional mutations in genes of known sequences
US20050130173A1 (en) * 2003-01-29 2005-06-16 Leamon John H. Methods of amplifying and sequencing nucleic acids
US7220549B2 (en) * 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US24939A (en) 1859-08-02 Improvement in sewing-machines
EP0124990B1 (fr) 1983-04-28 1987-08-19 Flexible Steel Lacing Company Procédé et dispositif de rivetage d'organes de fixation sur une courroie
EP0456721A4 (en) 1989-01-31 1992-06-03 University Of Miami Microdissection and amplification of chromosomal dna
EP0534858B2 (fr) 1991-09-24 2005-04-27 Keygene N.V. Amplification sélective des fragments de restriction: procédé général pour le "fingerprinting" d'ADN
US20100267023A1 (en) 1992-09-24 2010-10-21 Keygene N.V. Selective restriction fragment amplification: fingerprinting
AU1682595A (en) 1994-01-21 1995-08-08 North Carolina State University Methods for within family selection in woody perennials using genetic markers
EG23907A (en) 1994-08-01 2007-12-30 Delta & Pine Land Co Control of plant gene expression
US6013445A (en) 1996-06-06 2000-01-11 Lynx Therapeutics, Inc. Massively parallel signature sequencing by ligation of encoded adaptors
WO1996017082A2 (fr) 1994-11-28 1996-06-06 E.I. Du Pont De Nemours And Company Sondes de microsatellites composes pour la detection de polymorphismes genetiques
US5565340A (en) 1995-01-27 1996-10-15 Clontech Laboratories, Inc. Method for suppressing DNA fragment amplification during PCR
US5935793A (en) * 1996-09-27 1999-08-10 The Chinese University Of Hong Kong Parallel polynucleotide sequencing method using tagged primers
CA2286864A1 (fr) 1997-01-10 1998-07-16 Pioneer Hi-Bred International, Inc. Amplification et analyse genetiques sur la base d'une hybridation
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
ES2163271T3 (es) 1997-05-13 2002-01-16 Azign Bioscience As Procedimiento para clonar arnm y visualizar transcriptores diferencialmente expresados (dodets).
CA2273616A1 (fr) 1998-06-08 1999-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methode de detection parallele de variation allelique
US6124201A (en) 1998-06-12 2000-09-26 Advanced Micro Devices, Inc. Method for manufacturing semiconductors with self-aligning vias
ATE244771T1 (de) 1998-07-29 2003-07-15 Keygene Nv Verfahren zur erkennung von nukleinsäuremethylierungen durch aflp
US6232067B1 (en) 1998-08-17 2001-05-15 The Perkin-Elmer Corporation Adapter directed expression analysis
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
EP1001037A3 (fr) 1998-09-28 2003-10-01 Whitehead Institute For Biomedical Research Pre-selection et isolement d'un polymorphisme de mononucleotide
WO2000024939A1 (fr) 1998-10-27 2000-05-04 Affymetrix, Inc. Gestion de la complexite et analyse d'adn genomique
US6480791B1 (en) 1998-10-28 2002-11-12 Michael P. Strathmann Parallel methods for genomic analysis
JP2002534098A (ja) 1999-01-06 2002-10-15 コーネル リサーチ ファンデーション インク． ゲノムシークエンシングにおける単一ヌクレオチドの多型の加速度的な同定およびクローンの整列化
US20040029155A1 (en) 1999-01-08 2004-02-12 Curagen Corporation Method for identifying a biomolecule
CA2358638A1 (fr) 1999-01-12 2000-07-20 Quanam Medical Corporation Composition et procedes permettant l'administration de derives de paclitaxel non solubles dans l'eau
DE19911130A1 (de) 1999-03-12 2000-09-21 Hager Joerg Verfahren zur Identifikation chromosomaler Regionen und Gene
AU778438B2 (en) 1999-04-06 2004-12-02 Yale University Fixed address analysis of sequence tags
CA2366374C (fr) 1999-04-09 2009-09-22 Keygene N.V. Methode de detection et/ou d'analyse, au moyen de techniques d'amorce extensives, de polymorphismes a nucleotide unique dans des fragments restrictifs, en particulier dans des fragments restrictifs amplifies produits au moyen d'aflp
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20020119448A1 (en) 1999-06-23 2002-08-29 Joseph A. Sorge Methods of enriching for and identifying polymorphisms
US20030204075A9 (en) 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
AU7712400A (en) 1999-09-23 2001-04-24 Gene Logic, Inc. Indexing populations
US6287778B1 (en) * 1999-10-19 2001-09-11 Affymetrix, Inc. Allele detection using primer extension with sequence-coded identity tags
US6958225B2 (en) 1999-10-27 2005-10-25 Affymetrix, Inc. Complexity management of genomic DNA
AU1413601A (en) 1999-11-19 2001-06-04 Takara Bio Inc. Method of amplifying nucleic acids
AU2001253063A1 (en) 2000-03-31 2001-10-15 Fred Hutchinson Cancer Research Center Reverse genetic strategy for identifying functional mutations in genes of known sequence
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1282729A2 (fr) 2000-05-15 2003-02-12 Keygene N.V. Microsatellites-afpl
US7300751B2 (en) 2000-06-30 2007-11-27 Syngenta Participations Ag Method for identification of genetic markers
GB0016742D0 (en) * 2000-07-10 2000-08-30 Simeg Limited Diagnostic method
CA2426824A1 (fr) * 2000-10-24 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Caracterisation multiplex directe d'adn genomique
US6958217B2 (en) * 2001-01-24 2005-10-25 Genomic Expression Aps Single-stranded polynucleotide tags
US7141364B1 (en) 2001-03-29 2006-11-28 Council Of Scientific And Industrial Research Universal primers for wildlife identification
WO2002083911A1 (fr) 2001-04-12 2002-10-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Production de plantes a tolerance amelioree au stress de secheresse ou a transpiration augmentee
WO2002086163A1 (fr) 2001-04-20 2002-10-31 Karolinska Innovations Ab Procedes d'analyse genomique a haut rendement mettant en oeuvre des microreseaux etiquetes au niveau de sites de restriction
WO2003020015A2 (fr) 2001-08-30 2003-03-13 Purdue Research Foundation Procedes de production de plantes transgeniques resistant aux contraintes osmotiques
EP1288301A1 (fr) 2001-08-31 2003-03-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Gene de resistance derivé de plantes
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003081988A2 (fr) 2002-03-27 2003-10-09 Agrinomics Llc Production de plantes a tolerance amelioree vis-a-vis de la secheresse
US6815167B2 (en) 2002-04-25 2004-11-09 Geneohm Sciences Amplification of DNA to produce single-stranded product of defined sequence and length
US20070065816A1 (en) 2002-05-17 2007-03-22 Affymetrix, Inc. Methods for genotyping
US7108976B2 (en) 2002-06-17 2006-09-19 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
WO2004001074A1 (fr) 2002-06-21 2003-12-31 Lynx Therapeutics, Inc. Procede de detection d'un adn etranger dans un genome hote
EP1546345B1 (fr) 2002-09-05 2007-03-28 Plant Bioscience Limited Partitionnement de genome
US20040157238A1 (en) * 2002-09-20 2004-08-12 Quinn John J. Method for detection of multiple nucleic acid sequence variations
WO2004035798A2 (fr) 2002-10-18 2004-04-29 Cropdesign N.V. Identification de nouveaux genes cibles e2f et leur utilisation
EP1573009B1 (fr) 2002-12-18 2011-09-21 Third Wave Technologies, Inc. Detection de petits acides nucleiques
JP2004208586A (ja) * 2002-12-27 2004-07-29 Wakunaga Pharmaceut Co Ltd Ｈｌａの検出
EP1581661B1 (fr) 2003-01-10 2012-09-12 Keygene N.V. Methode d' integration de cartes physiques et genetiques par aflp
CA2555962C (fr) 2003-02-26 2015-10-06 Callida Genomics, Inc. Analyse de reseau d'adn aleatoire par hybridation
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
ATE506442T1 (de) 2003-06-24 2011-05-15 Agrigenetics Inc Erzeugung von pflanzen mit verbesserter toleranz gegenüber trockenheit
WO2005002325A2 (fr) 2003-06-24 2005-01-13 Agrinomics Llc Production de plantes a meilleure tolerance a la secheresse
US7051935B2 (en) 2003-07-28 2006-05-30 Imageid Ltd. Color calibration for color bar codes
WO2005026686A2 (fr) 2003-09-09 2005-03-24 Compass Genetics, Llc Plate-forme analytique multiplexee
WO2005037987A2 (fr) * 2003-10-21 2005-04-28 The Volcani Center- The State Of Israel, Ministry Of Agriculture, Agricultural Research Organization Sequences nucleotidiques isolees responsables des phenotypes mutants de high pigment 1 de la tomate (hp-1 et hp-1w) et utilisations associees
US20050153317A1 (en) 2003-10-24 2005-07-14 Metamorphix, Inc. Methods and systems for inferring traits to breed and manage non-beef livestock
EP3175914A1 (fr) 2004-01-07 2017-06-07 Illumina Cambridge Limited Perfectionnements apportés ou se rapportant à des réseaux moléculaires
US20050233354A1 (en) 2004-01-22 2005-10-20 Affymetrix, Inc. Genotyping degraded or mitochandrial DNA samples
AU2005214329A1 (en) 2004-02-12 2005-09-01 Population Genetics Technologies Ltd Genetic analysis by sequence-specific sorting
US7709262B2 (en) * 2004-02-18 2010-05-04 Trustees Of Boston University Method for detecting and quantifying rare mutations/polymorphisms
EP1574585A1 (fr) 2004-03-12 2005-09-14 Plant Research International B.V. Méthode pour l'amplification sélectif des fragments d'ADN pour l'empreinte génétique
JP4809594B2 (ja) 2004-08-02 2011-11-09 東京エレクトロン株式会社 検査装置
FR2876479B1 (fr) 2004-10-11 2006-12-15 Parkeon Machine a pieces a receptacle de pieces de monnaie amovible
US7407757B2 (en) 2005-02-10 2008-08-05 Population Genetics Technologies Genetic analysis by sequence-specific sorting
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
US20070009925A1 (en) * 2005-05-05 2007-01-11 Applera Corporation Genomic dna sequencing methods and kits
EP1885882B1 (fr) 2005-05-10 2011-01-26 State of Oregon acting by & through the State Board of Higher Eduction on behalf of the University of Oregon Procedes pour mapper les polymorphismes et microreseaux de polymorphismes
EP2463386B1 (fr) 2005-06-15 2017-04-12 Complete Genomics Inc. Analyse d'acide nucléique par des mélanges aléatoires de fragments non chevauchants
CN105039313B (zh) 2005-06-23 2018-10-23 科因股份有限公司 用于多态性的高通量鉴定和检测的策略
CA2613248A1 (fr) 2005-06-23 2006-12-28 Keygene N.V. Strategies ameliorees pour le sequencage de genomes complexes utilisant des techniques de sequencage a haut rendement
US20070020640A1 (en) 2005-07-21 2007-01-25 Mccloskey Megan L Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis
US10316364B2 (en) 2005-09-29 2019-06-11 Keygene N.V. Method for identifying the source of an amplicon
DK1929039T4 (en) 2005-09-29 2014-02-17 Keygene Nv High throughput-screening af mutageniserede populationer
CN101310024B (zh) 2005-11-14 2012-10-03 科因股份有限公司 高通量筛选转座子标记群体和大量平行的插入位点的序列鉴定方法
EP2789696B1 (fr) 2005-12-22 2015-12-16 Keygene N.V. Procédé pour la détection de polymorphisme à base AFLP à haut rendement
WO2007087312A2 (fr) 2006-01-23 2007-08-02 Population Genetics Technologies Ltd. Décompte moléculaire
EP2963127B1 (fr) 2006-04-04 2017-08-16 Keygene N.V. Détection à haut débit de marqueurs moléculaires sur la base de fragments de restriction
US8362325B2 (en) 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
US20090124758A1 (en) 2007-11-09 2009-05-14 Bridgestone Sports Co., Ltd. Golf ball
US20140051585A1 (en) 2012-08-15 2014-02-20 Natera, Inc. Methods and compositions for reducing genetic library contamination
CA2913236A1 (fr) 2013-06-07 2014-12-11 Keygene N.V. Methode de sequencage cible

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248526B1 (en) * 1997-12-15 2001-06-19 Aventis Behring, Gmbh Labeled primer for use in and detection of target nucleic acids
US20040053236A1 (en) * 2001-03-30 2004-03-18 Mccallum Claire M. Reverse genetic strategy for identifying functional mutations in genes of known sequences
US20050130173A1 (en) * 2003-01-29 2005-06-16 Leamon John H. Methods of amplifying and sequencing nucleic acids
US7220549B2 (en) * 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing

Cited By (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143908A1 (en) * 2006-11-15 2010-06-10 Biospherex, Llc, A Limited Liability Company Multitag sequencing ecogenomics analysis-us
US8603749B2 (en) * 2006-11-15 2013-12-10 Biospherex, LLC Multitag sequencing ecogenomics analysis-US
US9453262B2 (en) 2006-11-15 2016-09-27 Biospherex, LLC Multitag sequencing ecogenomics analysis-us
US20140296090A1 (en) * 2008-08-26 2014-10-02 Fluidigm Corporation Assay methods for increased throughput of samples and/or targets
US10344318B2 (en) 2009-04-02 2019-07-09 Fluidigm Corporation Multi-primer amplification method for barcoding of target nucleic acids
US9677119B2 (en) 2009-04-02 2017-06-13 Fluidigm Corporation Multi-primer amplification method for tagging of target nucleic acids
US11795494B2 (en) 2009-04-02 2023-10-24 Fluidigm Corporation Multi-primer amplification method for barcoding of target nucleic acids
US11447822B2 (en) 2009-04-30 2022-09-20 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11499188B2 (en) 2009-04-30 2022-11-15 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11499187B2 (en) 2009-04-30 2022-11-15 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11352665B2 (en) 2009-04-30 2022-06-07 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US11339432B2 (en) 2009-04-30 2022-05-24 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10501793B2 (en) 2009-04-30 2019-12-10 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10266884B2 (en) 2009-04-30 2019-04-23 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US10266883B2 (en) 2009-04-30 2019-04-23 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US20120276524A1 (en) * 2009-11-16 2012-11-01 Genomictree, Inc. Genotyping method
US9695473B2 (en) 2009-11-16 2017-07-04 Genomictree, Inc. Genotyping method
US11767550B2 (en) 2010-04-05 2023-09-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11549138B2 (en) 2010-04-05 2023-01-10 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10472669B2 (en) 2010-04-05 2019-11-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10480022B2 (en) 2010-04-05 2019-11-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10494667B2 (en) 2010-04-05 2019-12-03 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11866770B2 (en) 2010-04-05 2024-01-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11401545B2 (en) 2010-04-05 2022-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11479810B1 (en) 2010-04-05 2022-10-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10612079B2 (en) 2010-04-05 2020-04-07 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10619196B1 (en) 2010-04-05 2020-04-14 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10662467B2 (en) 2010-04-05 2020-05-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10662468B2 (en) 2010-04-05 2020-05-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11384386B2 (en) 2010-04-05 2022-07-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11371086B2 (en) 2010-04-05 2022-06-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10914730B2 (en) 2010-04-05 2021-02-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11761030B2 (en) 2010-04-05 2023-09-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10961566B2 (en) 2010-04-05 2021-03-30 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10962532B2 (en) 2010-04-05 2021-03-30 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10982268B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10983113B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10996219B2 (en) 2010-04-05 2021-05-04 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001878B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001879B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11008607B2 (en) 2010-04-05 2021-05-18 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11732292B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays correlating target nucleic acid to tissue section location
US11067567B2 (en) 2010-04-05 2021-07-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11156603B2 (en) 2010-04-05 2021-10-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11634756B2 (en) 2010-04-05 2023-04-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11208684B2 (en) 2010-04-05 2021-12-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11560587B2 (en) 2010-04-05 2023-01-24 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10308982B2 (en) 2010-04-05 2019-06-04 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11293917B2 (en) 2010-04-05 2022-04-05 Prognosys Biosciences, Inc. Systems for analyzing target biological molecules via sample imaging and delivery of probes to substrate wells
US11365442B2 (en) 2010-04-05 2022-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11313856B2 (en) 2010-04-05 2022-04-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11542543B2 (en) 2010-04-05 2023-01-03 Prognosys Biosciences, Inc. System for analyzing targets of a tissue section
US11519022B2 (en) 2010-04-05 2022-12-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
EP2599877A4 (fr) * 2010-06-30 2014-01-01 Bgi Shenzhen Co Ltd Nouvelle méthode de séquençage par pcr et son utilisation dans le génotypage hla
AU2011274090B2 (en) * 2010-06-30 2015-04-09 Bgi Genomics Co., Ltd New PCR sequencing method and use thereof in HLA genotyping
EP2599877A1 (fr) * 2010-06-30 2013-06-05 BGI Shenzhen Co., Limited Nouvelle méthode de séquençage par pcr et son utilisation dans le génotypage hla
US9957564B2 (en) 2010-06-30 2018-05-01 Bgi Genomics Co., Ltd. Application of a PCR sequencing method, based on DNA barcoding technique and DNA incomplete shearing strategy, in HLA genotyping
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11479809B2 (en) 2011-04-13 2022-10-25 Spatial Transcriptomics Ab Methods of detecting analytes
US11788122B2 (en) 2011-04-13 2023-10-17 10X Genomics Sweden Ab Methods of detecting analytes
US11795498B2 (en) 2011-04-13 2023-10-24 10X Genomics Sweden Ab Methods of detecting analytes
US11293063B2 (en) 2011-05-13 2022-04-05 Mount Sinai School Of Medicine Pooled adapter strategy for reducing bias in small RNA characterization
US10557169B2 (en) 2011-05-13 2020-02-11 Mount Sinai School Of Medicine Pooled adapter strategy for reducing bias in small RNA characterization
US20120322691A1 (en) * 2011-05-13 2012-12-20 Ravi Sachidanandam Pooled adapter strategy for reducing bias in small rna characterization
US9487825B2 (en) * 2011-05-13 2016-11-08 Mount Sinai School Of Medicine Pooled adapter strategy for reducing bias in small RNA characterization
US10501786B2 (en) 2011-05-20 2019-12-10 Fluidigm Corporation Nucleic acid encoding reactions
US12018323B2 (en) 2011-05-20 2024-06-25 Fluidigm Corporation Nucleic acid encoding reactions
US20150045258A1 (en) * 2012-02-14 2015-02-12 Gnubio, Inc. Cascaded addition of target specific universal adapters to nucleic acids
US9840732B2 (en) 2012-05-21 2017-12-12 Fluidigm Corporation Single-particle analysis of particle populations
USRE50065E1 (en) 2012-10-17 2024-07-30 10X Genomics Sweden Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US11753674B2 (en) 2013-06-25 2023-09-12 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11046996B1 (en) 2013-06-25 2021-06-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10774372B2 (en) 2013-06-25 2020-09-15 Prognosy s Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11359228B2 (en) 2013-06-25 2022-06-14 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11821024B2 (en) 2013-06-25 2023-11-21 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11618918B2 (en) 2013-06-25 2023-04-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10927403B2 (en) 2013-06-25 2021-02-23 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11286515B2 (en) 2013-06-25 2022-03-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11613773B2 (en) 2015-04-10 2023-03-28 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11739372B2 (en) 2015-04-10 2023-08-29 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11299774B2 (en) 2015-04-10 2022-04-12 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11117113B2 (en) 2015-12-16 2021-09-14 Fluidigm Corporation High-level multiplex amplification
US11857940B2 (en) 2015-12-16 2024-01-02 Fluidigm Corporation High-level multiplex amplification
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11933957B1 (en) 2018-12-10 2024-03-19 10X Genomics, Inc. Imaging system hardware
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11753675B2 (en) 2019-01-06 2023-09-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11965213B2 (en) 2019-05-30 2024-04-23 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11702698B2 (en) 2019-11-08 2023-07-18 10X Genomics, Inc. Enhancing specificity of analyte binding
US11981965B2 (en) 2019-12-23 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11560593B2 (en) 2019-12-23 2023-01-24 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11795507B2 (en) 2019-12-23 2023-10-24 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11332790B2 (en) 2019-12-23 2022-05-17 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11505828B2 (en) 2019-12-23 2022-11-22 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US12117439B2 (en) 2019-12-23 2024-10-15 10X Genomics, Inc. Compositions and methods for using fixed biological samples
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US12076701B2 (en) 2020-01-31 2024-09-03 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US12129516B2 (en) 2020-02-07 2024-10-29 10X Genomics, Inc. Quantitative and automated permeabilization performance evaluation for spatial transcriptomics
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11535887B2 (en) 2020-04-22 2022-12-27 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11773433B2 (en) 2020-04-22 2023-10-03 10X Genomics, Inc. Methods for spatial analysis using targeted RNA depletion
US11608520B2 (en) 2020-05-22 2023-03-21 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11959130B2 (en) 2020-05-22 2024-04-16 10X Genomics, Inc. Spatial analysis to detect sequence variants
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11866767B2 (en) 2020-05-22 2024-01-09 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11560592B2 (en) 2020-05-26 2023-01-24 10X Genomics, Inc. Method for resetting an array
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
US11781130B2 (en) 2020-06-08 2023-10-10 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11407992B2 (en) 2020-06-08 2022-08-09 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11624063B2 (en) 2020-06-08 2023-04-11 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11492612B1 (en) 2020-06-08 2022-11-08 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US11434524B2 (en) 2020-06-10 2022-09-06 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
US11661626B2 (en) 2020-06-25 2023-05-30 10X Genomics, Inc. Spatial analysis of DNA methylation
US12060604B2 (en) 2020-06-25 2024-08-13 10X Genomics, Inc. Spatial analysis of epigenetic modifications
US11408029B2 (en) 2020-06-25 2022-08-09 10X Genomics, Inc. Spatial analysis of DNA methylation
US11952627B2 (en) 2020-07-06 2024-04-09 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
US11873482B2 (en) 2020-12-21 2024-01-16 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11959076B2 (en) 2020-12-21 2024-04-16 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US11680260B2 (en) 2020-12-21 2023-06-20 10X Genomics, Inc. Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US11618897B2 (en) 2020-12-21 2023-04-04 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US12071655B2 (en) 2021-06-03 2024-08-27 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
US11840724B2 (en) 2021-09-01 2023-12-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
US11753673B2 (en) 2021-09-01 2023-09-12 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array

Also Published As

Publication number Publication date
US20140080716A1 (en) 2014-03-20
ES2338459T5 (es) 2014-02-24
CA2910861C (fr) 2018-08-07
US20170166962A1 (en) 2017-06-15
WO2007037678A3 (fr) 2007-05-31
US10538806B2 (en) 2020-01-21
US9670542B2 (en) 2017-06-06
CN101313078B (zh) 2013-04-10
WO2007037678A2 (fr) 2007-04-05
EP1929039B2 (fr) 2013-11-20
US10233494B2 (en) 2019-03-19
US20170022560A1 (en) 2017-01-26
EP1929039B1 (fr) 2009-12-30
US11649494B2 (en) 2023-05-16
US8614073B2 (en) 2013-12-24
US20160258006A1 (en) 2016-09-08
JP5237099B2 (ja) 2013-07-17
DE602006011486D1 (de) 2010-02-11
US9657335B2 (en) 2017-05-23
DK1929039T4 (en) 2014-02-17
US20120309633A1 (en) 2012-12-06
ATE453728T1 (de) 2010-01-15
US20170342486A1 (en) 2017-11-30
US9376719B2 (en) 2016-06-28
JP2009509527A (ja) 2009-03-12
US20190153534A1 (en) 2019-05-23
AU2006295556A1 (en) 2007-04-05
CN101313078A (zh) 2008-11-26
AU2006295556B2 (en) 2012-07-05
DK1929039T3 (da) 2010-03-08
US20170159120A1 (en) 2017-06-08
US9745627B2 (en) 2017-08-29
EP1929039A2 (fr) 2008-06-11
US9574230B2 (en) 2017-02-21
CA2910861A1 (fr) 2007-04-05
CA2623539A1 (fr) 2007-04-05
US20170114405A1 (en) 2017-04-27
US20200291471A1 (en) 2020-09-17
ES2338459T3 (es) 2010-05-07
CA2623539C (fr) 2015-12-15
US20180245151A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
US11649494B2 (en) High throughput screening of populations carrying naturally occurring mutations
US9328383B2 (en) Method for high-throughput AFLP-based polymorphism detection
US20090208943A1 (en) Method for the High Throughput Screening of Transposon Tagging Populations and Massive Parallel Sequence Identification of Insertion Sites
US20200102612A1 (en) Method for identifying the source of an amplicon

Legal Events

Date Code Title Description
AS Assignment

Owner name: KEYGENE N.V, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN EIJK, MICHAEL JOSEPHUS THERESIA;VAN TUNEN, ADRIANUS JOHANNES;REEL/FRAME:021496/0714

Effective date: 20080724

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION